Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full financial figures and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- SPY001 and SPY002 achieved primary endpoints in UC, with clinical remission rates of 40% and 33%, respectively
- Endoscopic improvement reached 51% for SPY001 and 42% for SPY002, supporting potential differentiation in IBD
- Six Phase 2 proof-of-concept readouts remain planned for 2026, including RA data in September and PsA and axSpA data in Q4
- Cash, equivalents, and marketable securities totaled $1,145.3 million at June 30, 2026, with runway into the second half of 2029
- Q2 net loss was $36.2 million, while R&D expense increased to $65.5 million from $40.1 million year over year
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.